Scribd Logo
Upload

Welcome to Scribd!

  • 73 views

    Atracurium

    Uploaded by

    Mohammed Ibrahim

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd

    Atracurium

    Uploaded by

    Mohammed Ibrahim
    73 views1 page

    Original Title

    atracurium

    Copyright

    © © All Rights Reserved

    Available Formats

    DOCX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    73 views1 page

    Atracurium

    Uploaded by

    Mohammed Ibrahim

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    You are on page 1of 1

    ATRACURIUM - TRACRIUM ®

    25mg,50 mg

    USUAL DILUENTS
    D5W, NS
    Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate]

    (Usual concentration: 0.2 to 5 mg/ ml)


    STABILITY / MISCELLANEOUS
    STABILITY DATA:

    Stability Stability Reconstituted P-Insert


    Drug Refrigerated Room Temp. Vial/Powder Notes Updated
    Parenteral drug
    products should be
    inspected visually for
    particulate matter and
    discoloration prior to
    Upon removal from administration,
    refrigeration to room whenever solution
    temperature storage and container permit.
    conditions Protect from light.
    (25°C/77°F), use Retain in carton until
    Store between 2° Atracurium Besylate time of use.
    and 8°C (36° and Injection within 14
    Atracuriu 46°F) to preserve days even if re- Do not freeze.
    m potency. refrigerated. Solution 08 18 16

    EXP: 24 hours (RT/REF) -admixture. May be given undiluted by IV bolus.


    Dosing (adult): initially 0.4 to 0.5 mg/kg IV bolus, followed by 0.08 to 0.1 mg/kg q20-45 min after initial dose.
    Continuous infusion: initially 0.4 to 0.5 mg IV bolus, followed by 9 to 10 mcg/kg/min initially. Maintenance infusion
    rates of 5 to 9 mcg/kg/min are usually adequate. (Range: 2 to 15 mcg/kg/min).
    Toxic metabolite (laudanosine) may accumulate in renal failure.
    [Supplied: 50 mg/5 ml ; 100 mg/10ml vial]

    CLINICAL PHARMACOLOGY
    Atracurium besylate is a nondepolarizing skeletal muscle relaxant. Nondepolarizing agents antagonize the
    neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the
    motor end-plate. This antagonism is inhibited, and neuromuscular block reversed, by acetylcholinesterase
    inhibitors such as neostigmine, edrophonium, and pyridostigmine.
    Atracurium can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to
    assess degree of muscle relaxation.

    The duration of neuromuscular block produced by atracurium is approximately one-third to one-half the duration of
    block by d-tubocurarine, metocurine, and pancuronium at initially equipotent doses. As with other nondepolarizing
    neuromuscular blockers, the time to onset of paralysis decreases and the duration of maximum effect increases with
    increasing atracurium doses.

    The ED95 (dose required to produce 95% suppression of the muscle twitch response with balanced anesthesia) has

    You might also like